mRNA Vaccines Market by Target Indication (RSV Infection, Metastatic / R / R Head and Neck Cancer, Influenza, Norovirus Acute Gastroenteritis, and Mononucleosis) and Geographical Regions (North America, Europe, and Asia-Pacific) - Trends and Forecast Till 2035

The global mRNA vaccines market (for non-COVID applications) is estimated to grow from USD 9 million in the current year to USD 7.04 billion by 2035, at an impressive CAGR of 109%, during the forecast period, till 2035.

mRNA Vaccines Market: Growth and Trends

mRNA vaccines represent a paradigm shift in preventive medicine. These vaccines rely on messenger ribonucleic acid (mRNA) to instruct host cells to manufacture a specific antigenic protein and, in turn, elicit a targeted immune response. Unlike conventional vaccine platforms that depend on live attenuated organisms, inactivated pathogens or recombinant proteins, the mRNA platform allows rapid design, scalable cell-free manufacturing and quick adaptability to emerging pathogens and antigenic drift. These significant features came to global prominence during the COVID-19 pandemic and are now being leveraged across a much broader set of indications.

The market is increasingly moving beyond its pandemic-driven origins toward a diversified mRNA vaccines opportunity, underpinned by expanding clinical pipelines and near-term commercialization prospects. Respiratory syncytial virus (RSV) remains a key area of focus, with multiple mRNA-based candidates progressing to address a significant unmet need among older adults and high-risk pediatric populations. Development activity is also intensifying across other respiratory and viral indications, including influenza and cytomegalovirus, reflecting the versatility of the mRNA modality across infectious disease prevention. Presently, over 100 mRNA-based candidates are presently being investigated for oncology-related indications alone, underscoring the platform's expansion well beyond its original scope. For instance, BioNTech has published its data on cancer vaccines that are currently in Phase II testing. These specialized therapies utilize patient-specific tumor sequencing to construct customized mRNA sequences matching an individual's unique neoantigens, aiming for a projected market launch window towards the end of the decade.

This market growth momentum is being reinforced by a growing number of mid- and late-stage clinical evidence supporting the immunogenicity, safety profile and rapid antigen-updating capability of mRNA vaccines. At present, several mRNA vaccines have secured regulatory approval, while a considerably larger number of candidates are advancing through late-stage clinical evaluation. For instance, Moderna’s Spikevax® has received the approval of supplemental Biologics License Application (sBLA) from the FDA, expanding its indication to high-risk pediatric populations (ages 6 months to 11 years) and older adults. While overall demand has normalized in the post-pandemic period, sustained investment in non-COVID vaccine development, manufacturing optimization and enabling delivery technologies is expected to support long-term market growth during the forecast period.

Growth Drivers: Factors Fueling Expansion of the Global mRNA Vaccines Market

Market expansion is being driven by the inherent speed and adaptability of the mRNA platform, which allows vaccine sequences to be designed and modified far more quickly than is possible with conventional approaches. These essential characteristics aid in resolving antigenic drift and emerging pathogens. Further, this has been complemented by steady advances in lipid nanoparticle delivery systems and large-scale, cell-free manufacturing capabilities, which have improved vaccine stability, production efficiency and commercial viability, while easing prior bottlenecks in global-scale distribution. Furthermore, the applications of the mRNA modality are broadening well beyond infectious disease prevention into oncology, rare diseases and personalized medicine, supported by encouraging early clinical results. Meanwhile, an emerging shift towards next-generation RNA platforms, including self-amplifying, circular and trans-amplifying RNA systems, is expected to further extend the durability and reach of the underlying technology, collectively positioning the mRNA vaccines market for sustained growth.

Market Challenges: Critical Barriers Hindering Progress

Despite this progressive outlook, the market continues to witness several challenges that impede overall growth. Demand for COVID-19 mRNA vaccines has normalized below pandemic-era levels, and the sector must now build a durable commercial base around non-COVID indications where reimbursement pathways, physician familiarity and public confidence are comparatively less established. Cold-chain storage and distribution requirements, though improving, continue to limit accessibility in cost-sensitive and infrastructure-constrained markets, while manufacturing capacity remains concentrated among a small number of established players, creating potential supply-side bottlenecks as pipeline candidates approach commercialization.

Moreover, regulatory pathways for novel, non-pandemic mRNA indications are still maturing in several geographies, extending development timelines relative to more established modalities. Additionally, as the number of mRNA-based candidates in active development rises across overlapping indications, such as influenza and RSV, competitive intensity and pricing pressure are likely to increase, requiring differentiated efficacy, dosing convenience or combination-vaccine strategies for developers to sustain commercial advantage.

mRNA Vaccines Market: Key Insights

The report delves into the current state of the mRNA vaccines market and identifies potential growth opportunities within the industry. Some key findings include:

• Presently, seven mRNA vaccines have secured regulatory approval and are commercially available. Moreover, a considerably larger pool of candidates is progressing through mid- and late-stage clinical trials across infectious disease and oncology indications.
• Over 100 mRNA-based candidates are currently being investigated for cancer-related indications, reflecting the platform's expansion well beyond its infectious disease origins.
• Close to 70% of ongoing clinical trials evaluating mRNA vaccines are being managed or funded by industry players, with Moderna emerging as the most active sponsor, followed by BioNTech and Sanofi; over half of the registered trials have already been completed.
• Over 1,060 patents related to mRNA vaccine technologies have been filed or granted worldwide, with filing activity accelerating sharply in the years following the COVID-19 pandemic as developers move to protect intellectual property spanning both infectious diseases and oncology applications.
• Partnership activity in this domain is intensifying. For instance, Moderna's February 2026 collaboration with the Mexican government to build a local mRNA ecosystem, spanning respiratory vaccine supply and technology transfer for domestic production.
• Among big pharma players actively partnering with smaller, specialized mRNA developers to build out their capabilities, Pfizer leads, followed by Sanofi, which has meaningfully expanded its mRNA-focused portfolio through such collaborations.
• In April 2026, Moderna's combination influenza and COVID-19 mRNA vaccine (mRNA-1083) received European Commission authorization, marking the first approved dual respiratory mRNA vaccine globally; separately, its seasonal influenza candidate (mFlusiva) is under active FDA review following data showing superior efficacy versus standard flu shots in adults aged 50-64.
• Given the breadth of the clinical pipeline, rising research and development investment and continued diversification into oncology and next-generation RNA platforms, the mRNA vaccines market is well positioned for sustained, high-growth expansion through the forecast period.

mRNA Vaccines Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Target Indication

• RSV Infection
• Metastatic / R/R Head and Neck Cancer
• Influenza
• Norovirus Acute Gastroenteritis
• Mononucleosis

By Geographical Regions

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Australia
• Middle East and North Africa
• Saudi Arabia
• UAE
• Latin America
• Brazil
• Argentina

mRNA Vaccines Market: Key Segments

Influenza is Poised to Emerge as the Leading Target Indication

Based on market analysis, the influenza segment is projected to capture the majority of overall market share by 2035. This growth is driven by mRNA’s ability to overcome major limitations of traditional flu vaccines. Influenza viruses evolve quickly, requiring frequent reformulation of conventional vaccines. mRNA technology enables much faster updates, allowing manufacturers to adjust the vaccine closer to flu season for a better strain match and improved effectiveness.

Moreover, influenza also offers a recurring, high-volume annual demand cycle that aligns closely with mRNA's scalable, cell-free manufacturing model, allowing the same production infrastructure to be reused each season with only sequence-level modifications, improving operating leverage and margin potential for manufacturers.

North America Holds the Highest Share

According to our projections, North America is expected to maintain its dominance as the largest and fastest-growing regional market for mRNA vaccines through 2035. This dominance is due to the region's early and concentrated investment in mRNA platform development. Recently, Moderna and Pfizer in collaboration with BioNTech established proprietary mRNA design, lipid nanoparticle delivery and large-scale manufacturing capabilities well ahead of the COVID-19 pandemic.

Additionally, substantial government risk-sharing support, most notably Operation Warp Speed, sped up clinical trials and regulatory approvals for mRNA vaccines. The FDA’s efficient and well-defined approval processes continue to facilitate faster market entry. A dominant intellectual property position in mRNA synthesis, modification and delivery technologies further reinforces high entry barriers for competitors in the region.

Europe and Asia-Pacific Offer Long-Term Opportunity

Beyond North America, Europe is expected to remain a significant contributor to global revenues, supported by the region's expanding biotech ecosystem, coordinated public health procurement and recent regulatory milestones such as the European Commission's authorization of Moderna's combination influenza-COVID-19 vaccine.

Further, Asia-Pacific’s mRNA vaccines market, while smaller in absolute terms, is expected to see growth momentum over the forecast period. This growth is likely to be driven by the growing domestic manufacturing initiatives across China and South Korea, rising government interest in pandemic-preparedness infrastructure, and an expanding base of local mRNA technology developers.

Example Players in mRNA Vaccines Market

• Arcturus Therapeutics
• BioNTech
• CureVac
• Ethris
• Gennova Biopharmaceuticals
• Immorna
• Innovac Therapeutics
• Kernal Biologics
• Moderna
• Providence Therapeutics
• Recode Therapeutics
• Rejuvenation Technologies
• RNACure
• RNAimmune
• Strand Therapeutics
• Suzhou Abogen Biosciences
• Turn Biotechnologies
• Walvax

Expert Interview and Industry Insights

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Business Development Manager, Mid-sized Organization, Australia
• Senior Director, Business Development, Large Organization, Belgium
• Team Leader, Large Organization, South Korea

In addition, the report features transcripts of third-party discussions with the following individuals:

• Director of Advanced Drug Delivery, Mid-sized Organization, UK
• Deputy Director, Mid-sized Organization, US
• Co-Founder and Chief Executive Officer, Mid-sized Organization, Germany
• Co-Founder, Large Organization, Germany
• Chief Executive Officer, Large Organization, US
• Chief Executive Officer, Mid-sized Organization, US
• Chief Executive Officer, Large Organization, Italy
• President, Mid-sized Organization, Switzerland
• Medical Professional, Large Organization, Germany

mRNA VACCINES MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the mRNA vaccines market, focusing on key market segments, including, target indication and geographical regions, using a top-down forecasting approach validated against primary research inputs.
• mRNA Vaccines Landscape: A detailed assessment of the overall mRNA vaccines development landscape, featuring information on parameters such as phase of development, target indication, route of administration and type of technology / RNA platform. It also features analysis of developers based on year of establishment, company size and location of headquarters.
• Company Profiles: In-depth profiles of prominent players engaged in the mRNA vaccines industry, featuring information on their year of establishment, location of headquarters, company size, management team, portfolio and key initiatives.
• Clinical Trial Analysis: An analysis of completed and ongoing clinical trials related to mRNA vaccines, based on parameters such as trial registration year, trial phase, trial status, type of sponsor / collaborator, study design and leading industry / non-industry players.
• Patent Analysis: An analysis of patents filed / granted related to mRNA vaccine technologies, based on parameters such as type of patent, publication year, jurisdiction, CPC symbols, type of applicant and patent valuation.
• Recent Developments: A detailed analysis of recent partnerships, funding and investments, and big pharma initiatives within this industry, based on several relevant parameters.
• Porter's Five Forces Analysis: A qualitative analysis of five competitive forces in this domain, namely, threat of new entrants, bargaining power of buyers, bargaining power of suppliers, threat of substitutes, and rivalry among existing competitors.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities and challenges affecting market growth.

Key Questions Answered in this Report

• Which are the leading companies in the mRNA vaccines market?
• Which region dominates the mRNA vaccines market?
• What are the key trends observed in the mRNA vaccines market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by mRNA vaccine developers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments; this information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities and challenges, empowering data-driven decision-making.
• The report can aid businesses in identifying future opportunities in this sector and in understanding whether those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences and behavior of the target audience, in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding this market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complementary Excel Data Packs for all Analytical Modules in the Report
• Up to 15% Complimentary Content Customization
• In-Depth Report Walkthrough with the Research Team
• Complimentary Report Update if the Report is 6+ Months Old